Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
62.84(c) 62.11(c) 62(c) 61.23(c) 61.31 Last
9 031 468 8 009 689 7 981 363 13 621 881 20 446 929 Volume
-0.46% -1.16% -0.18% -1.24% +0.13% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 46 378 M - -
Net income 2021 6 495 M - -
Net Debt 2021 28 289 M - -
P/E ratio 2021 21,2x
Yield 2021 3,21%
Sales 2022 48 244 M - -
Net income 2022 8 023 M - -
Net Debt 2022 17 834 M - -
P/E ratio 2022 16,4x
Yield 2022 3,36%
Capitalization 136 B 136 B -
EV / Sales 2021 3,54x
EV / Sales 2022 3,19x
Nbr of Employees 30 250
Free-Float 76,0%
More Financials
Company
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are... 
Sector
Pharmaceuticals
Calendar
09/16 | 02:30amPresentation
More about the company
Ratings of Bristol-Myers Squibb Company
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about BRISTOL-MYERS SQUIBB COMPANY
07:31aBRISTOL MYERS SQUIBB : Combination Therapy Gets EMA Committee's Backing for Trea..
MT
07:00aBRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion for Opdivo (nivolumab) + C..
BU
05:30aBristol Myers Gets Positive CHMP Opinion for Opdivo in Gastric, Esophageal Ca..
DJ
09/16Bristol-Myers Squibb Down Nine Consecutive Days, on Pace for Longest Losing S..
DJ
09/16BRISTOL MYERS SQUIBB : Reports Data From Phase 3 Trial of Opdivo, Yervoy Combina..
MT
09/16BRISTOL MYERS SQUIBB : Five-Year Data from CheckMate -214 Show Opdivo (nivolumab..
BU
09/16EXELIXIS : Says New Exploratory Data from Late-Stage Trial Show Potential of Kid..
MT
09/13BRISTOL MYERS SQUIBB : Says Phase 3 Trial of Opdivo Combined With Yervoy for Org..
MT
09/13BRISTOL MYERS SQUIBB : According to New Multinational Survey, Healthcare Provide..
BU
09/13BRISTOL MYERS SQUIBB : Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates ..
BU
09/13Bristol-Myers Squibb Company Announces Three-Year Data from the Checkmate -74..
CI
09/13TreeFrog Therapeutics announced that it has received €64 million in funding f..
CI
09/10BRISTOL MYERS SQUIBB : Shares Research Supporting Correlation Between New York H..
BU
09/09BRISTOL MYERS SQUIBB : Maintains Cash Dividend at $0.49 per common share, payabl..
MT
09/09BRISTOL MYERS SQUIBB : Announces Dividend
BU
More news
News in other languages on BRISTOL-MYERS SQUIBB COMPANY
09/16Exelixis déclare que de nouvelles données exploratoires issues d'un essai de ..
09/09Bristol Myers Squibb annonce le versement d'un dividende trimestriel, payable..
09/07Pharma-Industrie geht von ausreichend Corona-Impfstoff für alle aus
09/03Sandoz Canada, filiale de Novartis, lance une version générique du médicament..
09/02Evotec erhält weitere Meilensteinzahlung von Bristol-Myers Squibb
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 61,23 $
Average target price 75,89 $
Spread / Average Target 23,9%
EPS Revisions
Managers and Directors
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY-1.29%136 060
JOHNSON & JOHNSON4.98%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.21.62%249 329
NOVO NORDISK A/S51.34%233 887
ELI LILLY AND COMPANY36.84%209 456